1. Home
  2. Directory
  3. Arkansas
  4. Little Rock
  5. Internal Medicine
  6. NPI Profile
  7. Prescriptions 1689097313

MR. SHARMILAN THANENDRARAJAN M.D.
Prescription History 1689097313
Internal Medicine - Hematology & Oncology in Little Rock, AR

NPI Status: Active since January 31, 2014

Contact Information

4301 WEST MARKHAM STREET
SLOT 816
LITTLE ROCK, AR
ZIP 72205
Phone: (501) 526-6990
Fax: (501) 526-2273

Get Directions

Prescription History for Informed Healthcare Decisions

Explore the verified Medicare Part D prescription history, volume metrics, and calculated drug costs for MR. SHARMILAN THANENDRARAJAN M.D., an active Hematology & Oncology specialist practicing in Little Rock, AR. Our medical registry currently tracks 4 unique pharmaceutical formulations prescribed by this provider, representing an estimated volume of 154 documented patient claims. Among these therapy options, the most frequently utilized medication is Revlimid, which accounts for 52 claims alone.

Medication Index

L
M
P
R
No matching medications currently found on file.

Lorazepam

Generic Formulation: LorazepamSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 35
30-Day Fills 35.0
Days Supply 38
AR State Average Benchmarks
Peer Average Claims52.0
Peer Average 30-Day Fills54.9
Peer Average Days Supply1,433
Conservative Utilization

This provider writes prescriptions for this formulation 32.7% less frequently than the standard regional baseline metric for practitioners inside AR. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $29.10 across this reporting matrix range.

Provider Avg Cost Per Claim

$0.83

State Avg Cost Per Claim

$8.62

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A benzodiazepine used as an anti-anxiety agent with few side effects. It also has hypnotic, anticonvulsant, and considerable sedative properties and has been proposed as a preanesthetic agent.

Therapeutic Applications

This medication is used to treat serious seizures that do not stop (status epilepticus). It is also used before surgeries or procedures to cause drowsiness, decrease anxiety, and cause forgetfulness about the procedure or surgery. Lorazepam belongs to a class of medications called benzodiazepines, which produce a calming effect on the brain and nerves (central nervous system). It is thought to work by increasing the effect of a certain natural chemical (GABA) in the brain.

Morphine Sulfate

Generic Formulation: Morphine SulfateSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 26
30-Day Fills 26.0
Days Supply 26
AR State Average Benchmarks
Peer Average Claims44.0
Peer Average 30-Day Fills44.7
Peer Average Days Supply1,113
Conservative Utilization

This provider writes prescriptions for this formulation 40.9% less frequently than the standard regional baseline metric for practitioners inside AR. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $19.49 across this reporting matrix range.

Provider Avg Cost Per Claim

$0.75

State Avg Cost Per Claim

$29.78

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

The principal alkaloid in opium and the prototype opiate analgesic and narcotic. Morphine has widespread effects in the central nervous system and on smooth muscle.

Therapeutic Applications

This medication is used to treat severe pain. Morphine belongs to a class of drugs known as opioid analgesics. It works in the brain to change how your body feels and responds to pain.

Pomalyst

Generic Formulation: PomalidomideSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 41
30-Day Fills 41.0
Days Supply 1,055
AR State Average Benchmarks
Peer Average Claims56.0
Peer Average 30-Day Fills56.1
Peer Average Days Supply1,531
Conservative Utilization

This provider writes prescriptions for this formulation 26.8% less frequently than the standard regional baseline metric for practitioners inside AR. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $860,177.99 across this reporting matrix range.

Provider Avg Cost Per Claim

$20,979.95

State Avg Cost Per Claim

$19,261.94

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Pomalidomide is used to treat certain types of cancers (such as multiple myeloma, Kaposi sarcoma). It works by slowing or stopping the growth of cancer cells.

Revlimid

Generic Formulation: LenalidomideSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 52
30-Day Fills 52.0
Days Supply 1,401
AR State Average Benchmarks
Peer Average Claims54.0
Peer Average 30-Day Fills54.5
Peer Average Days Supply1,493
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across AR. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $928,183.67 across this reporting matrix range.

Provider Avg Cost Per Claim

$17,849.69

State Avg Cost Per Claim

$17,763.37

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A phthalimide and piperidone derivative that has immunomodulatory and antiangiogenic properties. It is used for the treatment of transfusion-dependent anemia in MYELODYSPLASTIC SYNDROMES, and for the treatment of MULTIPLE MYELOMA, and relapsed or refractory MANTLE CELL LYMPHOMA.

Therapeutic Applications

Lenalidomide is used to treat various types of cancers. It works by slowing or stopping the growth of cancer cells. It is also used to treat anemia in patients with certain blood/bone marrow disorders (myelodysplastic syndromes-MDS). Lenalidomide may lessen the need for blood transfusions. Lenalidomide is not recommended for the treatment of a certain type of cancer (chronic lymphocytic leukemia) because of the increased risk of serious heart-related side effects and death. If you have this type of cancer, talk to your doctor about the risks of using this medication.

Dataset Methodology & CMS Source Information

This analytical profile maps public infrastructure records sourced directly from official **Centers for Medicare & Medicaid Services (CMS)** public data releases. The statistics above track documented pharmaceutical treatment trends assigned to beneficiaries specifically under federal public programs. Evaluating the prescriptive footprints of clinical practitioners like MR. SHARMILAN THANENDRARAJAN M.D. provides transparency into local medical care patterns within Little Rock, AR.

Key Learning Objectives for this Profile:

  • Prescribing Frequencies: Track and evaluate the volume metrics of specific brand-name and generic medical formulas chosen by this provider over time.
  • Clinical Focus Areas: Identify how the provider distributes therapeutic selections across medical care options to gain insight into their true day-to-day **Hematology & Oncology** practice concentrations.
  • Program Cost Awareness: Review the calculated total systemic drug costs and raw transactional volumes linked to these orders to better anticipate network insurance coverage structures.
  • Patient-Centered Evaluation: Cross-reference localized regional care comparisons to align practitioner habits directly with your proactive health maintenance goals.

Data Scope Exclusion & Limitations: The data elements presented above explicitly reflect prescription orders processed for Medicare beneficiaries during the year 2023. This informational profile does not aggregate prescription data for individuals utilizing private commercial health plans, state Medicaid coverage, or self-pay options. However, because medical decision-making remains highly consistent across clinical settings, this public registry provides a reliable proxy for understanding the general prescribing preferences and pharmaceutical care approach used by this provider.